CA2137832A1 - Inhibitors of Angiotensin I Chymase(s) Including Human Heart Chymase - Google Patents
Inhibitors of Angiotensin I Chymase(s) Including Human Heart ChymaseInfo
- Publication number
- CA2137832A1 CA2137832A1 CA 2137832 CA2137832A CA2137832A1 CA 2137832 A1 CA2137832 A1 CA 2137832A1 CA 2137832 CA2137832 CA 2137832 CA 2137832 A CA2137832 A CA 2137832A CA 2137832 A1 CA2137832 A1 CA 2137832A1
- Authority
- CA
- Canada
- Prior art keywords
- chymase
- angiotensin
- inhibitors
- including human
- human heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003858 Chymases Human genes 0.000 title 2
- 108090000227 Chymases Proteins 0.000 title 2
- 101800000734 Angiotensin-1 Proteins 0.000 title 1
- 102400000344 Angiotensin-1 Human genes 0.000 title 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 2
- 230000003966 vascular damage Effects 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A compound of formula (I) which is effective for treating or preventing hypertension, congestive heart failure myocardial infarction, cardiac and left ventricular hypertrophy, coronary artery disease including myocardial infarction, vascular hypertrophy, and vascular damage following diabetic and non-diabetic renal disease, and vascular damage associated with angioplasty and aetheroma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89772392A | 1992-06-12 | 1992-06-12 | |
US897,723 | 1992-06-12 | ||
PCT/US1993/003625 WO1993025574A1 (en) | 1992-06-12 | 1993-04-23 | Inhibitors of angiotensin i chymase(s) including human heart chymase |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2137832A1 true CA2137832A1 (en) | 1993-12-23 |
CA2137832C CA2137832C (en) | 2000-09-26 |
Family
ID=25408314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002137832A Expired - Fee Related CA2137832C (en) | 1992-06-12 | 1993-04-23 | Inhibitors of angiotensin i chymase(s) including human heart chymase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0644892A1 (en) |
JP (1) | JP2668003B2 (en) |
CA (1) | CA2137832C (en) |
FI (1) | FI932695A (en) |
WO (1) | WO1993025574A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9524267D0 (en) * | 1995-11-28 | 1996-01-31 | Isis Innovation | Enzyme inhibitor and method |
DE59712953D1 (en) * | 1996-09-10 | 2008-09-04 | Boehringer Ingelheim Pharma | Modified amino acids, pharmaceutical compositions containing these compounds and methods for their preparation |
EP1136498A1 (en) * | 1996-10-18 | 2001-09-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease |
UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
EP0940400A4 (en) * | 1996-10-25 | 2002-10-02 | Mitsubishi Pharma Corp | Novel heterocyclic amide compounds and medicinal uses thereof |
US20030069231A1 (en) * | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
EP1055683A4 (en) * | 1998-02-17 | 2007-07-25 | Nippon Kayaku Kk | Novel acetamide derivative and use thereof |
WO2000010605A2 (en) * | 1998-08-20 | 2000-03-02 | Senju Pharmaceutical Co., Ltd. | Preventives or remedies for eye circulatory failure |
US6432978B1 (en) * | 1998-12-01 | 2002-08-13 | Meiji Seika Kaisha, Ltd. | SF2809-I,II,III,IV,V and VI substances exhibiting chymase-inhibiting activities |
HUP0104952A3 (en) | 1999-11-01 | 2006-02-28 | Daiichi Asubio Pharma Co Ltd | Inhibitors against vascular lipid deposition containing chymase-inhibiting substances |
EP1192949A4 (en) | 2000-02-22 | 2005-11-09 | Daiichi Suntory Pharma Co Ltd | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
EP1174151B1 (en) | 2000-02-22 | 2007-01-24 | Daiichi Asubio Pharma Co., Ltd. | Therapeutic treatment of eosinophilia using chymase inhibitors as the active ingredient |
WO2001062294A1 (en) | 2000-02-22 | 2001-08-30 | Suntory Limited | Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient |
AU779041B2 (en) * | 2000-05-02 | 2005-01-06 | Meiji Seika Kaisha Ltd. | Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof |
WO2002006280A2 (en) * | 2000-07-13 | 2002-01-24 | Millennium Pharamaceuticals, Inc. | INHIBITORS OF FACTOR Xa |
GB0021315D0 (en) | 2000-08-30 | 2000-10-18 | Dainippon Pharmaceutical Co | Heterocyclic compounds and intermediates thereof |
WO2002059077A1 (en) | 2001-01-26 | 2002-08-01 | Takeda Chemical Industries, Ltd. | Aminoethanol derivatives |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
CN100477995C (en) | 2003-05-09 | 2009-04-15 | 东丽株式会社 | Fortifier |
TW201127828A (en) | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
DE102004015723A1 (en) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals |
WO2008008502A1 (en) | 2006-07-13 | 2008-01-17 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
PT2364309E (en) | 2008-12-10 | 2015-01-14 | Achillion Pharmaceuticals Inc | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
KR20160005686A (en) | 2013-03-15 | 2016-01-15 | 아칠리온 파르마세우티칼스 인코포레이티드 | Sovaprevir polymorphs and methods of manufacture thereof |
EP4257191A3 (en) | 2016-06-21 | 2023-11-22 | Orion Ophthalmology LLC | Heterocyclic prolinamide derivatives |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
CA2021660A1 (en) * | 1989-07-26 | 1991-01-27 | Philippe Bey | Peptidase inhibitors |
EP0587799B1 (en) * | 1991-05-23 | 1999-07-07 | Merrell Pharmaceuticals Inc. | Inhibitors of cathepsin g and elastase for preventing connective tissue degradation |
-
1993
- 1993-04-23 EP EP93909587A patent/EP0644892A1/en not_active Withdrawn
- 1993-04-23 JP JP6501449A patent/JP2668003B2/en not_active Expired - Fee Related
- 1993-04-23 WO PCT/US1993/003625 patent/WO1993025574A1/en not_active Application Discontinuation
- 1993-04-23 CA CA002137832A patent/CA2137832C/en not_active Expired - Fee Related
- 1993-06-11 FI FI932695A patent/FI932695A/en unknown
Also Published As
Publication number | Publication date |
---|---|
FI932695A (en) | 1993-12-13 |
JPH07507069A (en) | 1995-08-03 |
JP2668003B2 (en) | 1997-10-27 |
EP0644892A1 (en) | 1995-03-29 |
CA2137832C (en) | 2000-09-26 |
FI932695A0 (en) | 1993-06-11 |
WO1993025574A1 (en) | 1993-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2137832A1 (en) | Inhibitors of Angiotensin I Chymase(s) Including Human Heart Chymase | |
CA2059000A1 (en) | Fused-ring aryl substituted imidazoles | |
CA2286272A1 (en) | Surgical retractor | |
CA2230931A1 (en) | 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency | |
CA2166983A1 (en) | Determining hemodynamic variables from a pressure sensor | |
CA2385997A1 (en) | Surgical retractor | |
WO2002071974A3 (en) | A stent for arterialization of the coronary sinus and retrograde perfusion of the myocardium | |
EP0487745A4 (en) | Pyridine derivative with angiotensin ii antagonism | |
DE69407785T2 (en) | BENZOYLBENZOFURANE DERIVATIVES FOR THE TREATMENT OF HEART ARRHYTHMIA | |
CA2030263A1 (en) | Implantable pharmacological defibrillator with automatic recognition of ventricular fibrillation | |
WO2001028992A3 (en) | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | |
CA2134972A1 (en) | Anti-ischemic medicament | |
EP1125580A3 (en) | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | |
CA2055637A1 (en) | Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia | |
CA2182062A1 (en) | Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents, and medicaments comprising them | |
CA2182477A1 (en) | Pyridyl Imidazole Derivatives and Processes for the Preparation Thereof | |
TW221438B (en) | ||
KUCK et al. | Pleomorphic ventricular tachycardia: demonstration of conduction reversal within the reentry circuit | |
CA2185394A1 (en) | Biotinderivate | |
Paulus | Upward shift and outward bulge. Divergent myocardial effects of pacing angina and brief coronary occlusion. | |
AU7750194A (en) | Linear adhesion inhibitors | |
Burggraf | The first heart sound in left bundle branch block: an echophonocardiographic study. | |
AU1855088A (en) | Treating agent for heart failure | |
EP0362152A3 (en) | Use of 3-indolepyruvic acid as a pharmaceutical agent for the inhibition of peripheral degenerative pathologies | |
EP0602246A4 (en) | Isoindazole compound. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |